Nautilus Biotechnology Inc expected to post a loss of 16 cents a share - Earnings Preview

Nautilus Biotechnology

25/02/2025 13:46

Nautilus Biotechnology Inc NAUT.OQ NAUT.O is expected to show no change in quarterly revenue when it reports  results on February 27 for the period ending December 31 2024

​LSEG's mean analyst estimate for Nautilus Biotechnology Inc is for a loss of 16 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Nautilus Biotechnology Inc is $3.00​, above​ its last closing price of $1.50. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.16
-0.16
-0.13
Beat
21.2
Jun. 30 2024
-0.16
-0.16
-0.14
Beat
14.6
Mar. 31 2024
-0.17
-0.16
-0.15
Beat
7.7​
Dec. 31 2023
-0.13
-0.14
-0.14
Met
3.4
​​Sep. 30 2023
-0.17
-0.17
-0.13
Beat
22.4
Jun. 30 2023
-0.14
-0.15
-0.13
Beat
13.3​
Mar. 31 2023
-0.16
-0.17
-0.12
Beat
28
Dec. 31 2022
-0.14
-0.15
-0.11
Beat
28.3

This summary was machine generated February 25 at 13:46 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)